NCT06445062 2026-03-13
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
Revolution Medicines, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Verastem, Inc.
University of Maryland, Baltimore
Peking University Cancer Hospital & Institute